TOKENPOST
1 min read
Add as a preferred source on Google

First Tracks Biotherapeutics Targets About $200 Million in Placement

The company agreed to sell about 6.11 million common shares at $32.75 each to institutional investors.

By John Kim
Published
A blank share certificate rests beside a clear vial / TokenPost.ai
A blank share certificate rests beside a clear vial / TokenPost.ai

First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) agreed to sell about 6.11 million common shares to institutional investors at $32.75 each, with the placement expected to generate about $200 million in gross proceeds.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…